A multifactorial algorithm to predict on-clopidogrel platelet reactivity as a potential way to improve the efficacy and safety of antiplatelet therapy
Abstract
Today the reasons for resistance to clopidogrel had not defined completely. Response to clopidogrel may depend on genetic and non-genetic factors. Therefore, a comprehensive approach is required, which considers characteristics of the patient, that will allow with high accuracy to estimate the risk of ischemic and hemorrhagic complications in a specific patient and give an opportunity for individualization of the choice of clopidogrel dosing modes. G. Miura et al. investigated the clinical and genetic factors which are responsible for the antiplatelet effect of clopidogrel in patients undergoing coronary stent implantation, and developed an algorithm to predict the pharmacodynamic response to this drug. There was found a correlation between PRU measured by VerifyNow-P2Y12 and PRU that was received from the original algorithm. It is the first research where was developed multifactorial algorithm to predict antiplatelet action of clopidogrel. Similar studies have not been carried through in the Russian population. The verification of prediction algorithm of the pharmacodynamic response to clopidogrel, developed by G. Miura et al., for Caucasians, particularly among the Russian population, is perspective.
About the Authors
N. P. Kurcheva
Sechenov I.M. First Moscow State Medical University
Russian Federation
Russian Federation
K. B. Mirzaev
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
D. A. Sychev
Sechenov I.M. First Moscow State Medical University; Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
References
1. Simon T., Verstuyft C., Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events. // N. Engl. J. Med. 2009. — Vol. 360. — P. 363—375.
2. Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. // Cardiovasc Ther 2011; 29:e100-111.
3. Morse B.L, Kim R.B. Is personalized medicine a dream or a reality? // Crit Rev Clin Lab Sci. 2015 Feb;52(1):1-11.
4. Karaniewicz-Łada M., Danielak D., Rubiś B., Burchardt P., Komosa A, Lesiak M, Główka F. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. // J Clin Pharm Ther. 2015. Apr;40(2):226-31.
5. Rudez G., Bouman H.J., van Werkum J.W., Leebeek F.W., Kruit A., Ruven H.J., et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. // Circ Cardiovasc Genet 2009;2:515—21.
6. Elsenberg E.H., van Werkum J.W., van de Wal R.M., et al. The influence of clinical characteristics, laboratory and inflammatory markers on “high on-treatment platelet reactivity” as measured with different platelet function tests. // Thromb Haemost 2009;102(4):719-27.
7. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. // JAMA 2010;303(8):754-62.
8. Jun-Feng Su, Xiao-Hui Hu, Cheng-Yan Li. Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. // Experimental and Therapeutic Medicine 9: 267-271, 2015.
9. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. // N Engl J Med 2009;360:354-362.
10. Под ред. В.Г. Кукеса., Н.П. Бочкова. Клиническая фармакогенетика: учебное пособие. Геотар-Медиа; 2007.
11. Miura G., Ariyoshi N., Sato Y., Yamaguchi H., Iwata Y., Fujimoto Y., Kobayashi Y., Ishii I. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity. // Thromb Res. 2014 Oct; 134(4):877-83.
12. Заключение междисциплинарного Совета Экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами, Национального научного общества воспаления. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. // Рациональная Фармакотерапия в Кардиологии 2014; 10(6): 679-87).
13. Tantry U.S., Bonello L., Aradi D., et al. Consensus and update on the defi nition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. // J Am Coll Cardiol 2013;62:2261-2273.
14. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. // J Am Coll Cardiol 2011;57:2474-2483.
15. Ahn S.G., Lee S.H., Yoon J.H., et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. // JACC Cardiovasc Interv 2012;5:259-267.
16. Park D.W., Ahn J.M., Song H.G., et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. // Am Heart J 2013;165:34-42.e1.
Review
For citations:
Kurcheva N.P., Mirzaev K.B., Sychev D.A. A multifactorial algorithm to predict on-clopidogrel platelet reactivity as a potential way to improve the efficacy and safety of antiplatelet therapy. Pharmacogenetics and Pharmacogenomics. 2015;(2):29-32. (In Russ.)
Views:
506
Email this article 
Post a Comment 